Skip to main content

Table 2 Renal and intraglomerular hemodynamics

From: Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

  E+L group M + I group E+L vs. M+I
Parameter Baseline 12 weeks Δ p-value Baseline 12 weeks Δ p-value padjust-value
RPF (ml/min)* 623 ± 114 615 ± 115 − 7.6 ± 86 0.536 653 ± 150 600 ± 121 − 52 ± 94 < 0.001 0.041
GFR (ml/min) 127 ± 13 120 ± 14 − 6.3 ± 12 0.003 127 ± 15 120 ± 13 − 6.7 ± 10 0.001 0.899
FF (%) 21.6 ± 3.1 20.9 ± 3.0 − 0.7 ± 2.7 0.151 21.2 ± 2.8 21.5 ± 3.2 0.38 ± 2.2 0.337 0.200
RBF (ml/min)* 1061 ± 199 1113 ± 220 53 ± 157 0.021 1112 ± 249 1036 ± 217 − 76 ± 159 0.002 < 0.001
RVR (mmHg)* 91 ± 20 84 ± 18 − 7 ± 15 0.001 87 ± 21 94 ± 21 7 ± 13 0.001 < 0.001
Pglom (mmHg) 61.6 ± 3.2 61.1 ± 3.4 − 0.46 ± 3.1 0.387 61.7 ± 3.1 60.9 ± 3.2 − 0.86 ± 2.6 0.073 0.661
RA (dyn*s/cm5) 2547 ± 880 2358 ± 734 − 189 ± 685 0.116 2579 ± 798 2835 ± 800 256 ± 485 0.006 0.023
RE (dyn*s/cm5) 2361 ± 407 2152 ± 389 − 208 ± 330 0.001 2316 ± 351 2349 ± 435 33 ± 298 0.538 0.011
RE/RA (−) 1.02 ± 0.36 1.01 ± 0.37 − 0.01 ± 0.4 0.836 0.96 ± 0.25 0.87 ± 0.2 − 0.09 ± 0.17 0.004 0.597
MAP (mmHg) 93.4 ± 8.6 90.3 ± 8.0 − 3.1 ± 8.0 0.009 92.5 ± 7.2 93.4 ± 6.8 1.0 ± 5.9 0.264 0.021
  1. Dara are means ± SD
  2. * N = 50 (E+L group) and N = 46 (M+I group), respectively
  3. N = 34 (E+L group) and N = 31 (M+I group), respectively